Degree: PhD 2008 (University of Manitoba)
Mailing Address: National Lab for HIV Immunology
Dr McLaren is an Adjunct Professor in the Department of Medical Microbiology and a Research Scientist with the National HIV and Retrovirology Lab at the Public Health Agency of Canada. Dr McLaren did his PhD at the University of Manitoba studying differences in transcriptional programming in CD4+ T cells of individuals resistant to infection with HIV. During his post-doctoral studies in the Division of Genetics at Brigham and Women’s Hospital, Harvard Medical School, Dr McLaren focused on identifying host genetic factors associated with elite HIV control. From there, Dr McLaren accepted a position as a Junior Group Leader in Bioinformatics at the Swiss Federal Institute of Technology in Lausanne, Switzerland where he worked to establish an international consortium of infectious disease researchers focused on studying the human genomics of infection. This group now has collected clinical and genetic data on >11,000 individuals and involves collaborators on 5 continents. In Dr McLaren’s current position, his group applies the tools of systems biology (including genomics, transcriptomics and microbiome studies) to questions surrounding differential susceptibility to infection. In particular, Dr McLaren is interested in using human genetic information to identify potential drug targets, improve vaccine responsiveness and improve patient response to therapy using a precision medicine approach.
For a listing of Dr. McLaren's PubMed articles, please click here
1. McLaren PJ, et al. Privacy-preserving genomic testing in the clinic – a model using HIV treatment. Genet in Med. 2016 Aug;18(8):814-22.
2. McLaren PJ et al. Common variants of large effect explain the majority of the host genetic contribution to HIV-1 control. Proc Natl Acad Sci. 2015 Nov 24;112(47):14658-63. DOI: 10.1073/pnas.1514867112. PMCID: PMC4664299.
3. Lehmann DS, Ribaudo HJ, Daar ES, Gulick RM, Haubrich RH, Robbins GK, de Bakker PIW, Haas DW, McLaren PJ. Genome-wide Association Study of Virologic Response with Efavirenz- or Abacavir-containing Regimens in AIDS Clinical Trials Group Protocols. Pharmacogenet Genomics. 2015 Feb;25(2):51-9.
4. McLaren PJ et al. Association study of common genetic variants and HIV-1 acquisition in 6,300 infected cases and 7,200 controls. PLoS Pathog. 2013;9(7):e1003515. DOI: 10.1371/journal.ppat.1003515. PMCID: PMC3723635.
5. Pereyra F*, Jia X*, McLaren PJ* et al The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science. 2010 Dec 10;330(6010):1551-7. DOI: 10.1126/science.1195271. PMCID: PMC3235490. *Equal contribution